Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiviral therapy.

B Oberg1

  • 1Department of Virology, Karolinska Institute, Stockholm, Sweden.

Journal of Acquired Immune Deficiency Syndromes
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Developing new therapies targeting human immunodeficiency virus (HIV) enzymes is crucial. While current drugs show efficacy, further research into selective inhibitors and animal model evaluation is needed for better HIV treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The patient enablement instrument for back pain: reliability, content validity, construct validity and responsiveness.

Health and quality of life outcomes·2021
Same author

Lower extremity muscle strength in soccer players.

Clinical biomechanics (Bristol, Avon)·2013
Same author

Tibial translation and muscle activation during rehabilitation exercises 5 weeks after anterior cruciate ligament reconstruction.

Scandinavian journal of medicine & science in sports·2009
Same author

Parent's conceptions of intensive group training. The case of cerebral palsy.

Disability and rehabilitation·2009
Same author

Predictive factors for arm pain, neck pain, neck specific disability and health after anterior cervical decompression and fusion.

Acta neurochirurgica·2005
Same author

Descriptions of functioning and health and relations to a gross motor classification in adults with cerebral palsy.

Disability and rehabilitation·2004
Same journal

T lymphocyte homeostasis after HIV seroconversion.

Journal of acquired immune deficiency syndromes·1994
Same journal

Improved detection of HTLV-II antibody using a whole viral lysate-based EIA.

Journal of acquired immune deficiency syndromes·1994
Same journal

Changes in HIV risk behavior among French heterosexuals: patterns of sexual monogamy and condom use between 1988 and 1991.

Journal of acquired immune deficiency syndromes·1994
Same journal

HTLV-I-associated myelopathy in Venezuela.

Journal of acquired immune deficiency syndromes·1994
Same journal

Autoantibodies to nucleosomes in HIV-1-infected patients.

Journal of acquired immune deficiency syndromes·1994
Same journal

Seroprevalence of HIV-1 and syphilis antibodies in blood donors in Gonder, Ethiopia, 1989-1993.

Journal of acquired immune deficiency syndromes·1994
See all related articles

Area of Science:

  • Virology
  • Pharmacology
  • Immunology

Background:

  • Human immunodeficiency virus (HIV) replication relies on complex machinery, presenting multiple therapeutic targets.
  • Viral enzymes, such as reverse transcriptase and protease, are key targets for antiviral drug development.
  • Current therapies like zidovudine demonstrate the effectiveness of targeting HIV enzymes, but necessitate the development of less toxic alternatives.

Purpose of the Study:

  • To explore the potential of targeting HIV viral enzymes for therapeutic intervention.
  • To highlight the need for developing more selective and less toxic HIV inhibitors.
  • To emphasize the importance of animal models in evaluating novel HIV inhibitors for clinical progression.

Main Methods:

  • Review of current understanding of HIV replication machinery and viral enzyme functions.

Related Experiment Videos

  • Analysis of existing therapeutic strategies targeting HIV enzymes.
  • Discussion on the role of structural and functional insights in designing selective inhibitors.
  • Emphasis on preclinical evaluation in animal models for drug candidate selection.

    • Main Results:

    • HIV reverse transcriptase is a validated target, exemplified by zidovudine, though improved toxicity profiles are desired.
    • HIV protease represents another promising target for inhibitor development.
    • Increased understanding of HIV protein structure and function facilitates the design of more specific antiviral agents.
    • Animal models are essential for efficient selection of compounds and combinations for clinical trials.

    Conclusions:

    • Targeting HIV viral enzymes remains a primary strategy for developing new anti-HIV therapies.
    • The development of novel, selective, and less toxic inhibitors is anticipated in the coming years.
    • While effective HIV replication control is likely, complete viral elimination from patients remains a distant goal.